Quarterly report pursuant to Section 13 or 15(d)

GENERAL (Details Narrative)

v3.21.2
GENERAL (Details Narrative)
$ / shares in Units, Number in Thousands, $ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended
Jul. 15, 2021
USD ($)
Jul. 02, 2021
USD ($)
Number
$ / shares
Apr. 19, 2021
USD ($)
Apr. 19, 2021
USD ($)
shares
Aug. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jul. 28, 2020
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Feb. 27, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Cash deposits     $ 1,250 $ 1,250                      
Proceeds from (Repayments of) Debt   $ 1,250                          
Additional amount of cash payment $ 250                            
Convertible notes payable   $ 3,500                          
Maturity date description   October 20, 2021 through April 8, 2025                          
Debt Instrument, Convertible, Conversion Price | $ / shares   $ 0.05                          
Debt instrument trading days | Number   20                          
Payments for repurchase amount   $ 1,170                          
Number of shares issued value           $ 1,699                  
Fair value description     90% probability for the Mandatory Conversion and 10% probability for the Optional / Maturity Conversion                        
investment write off         $ 618                    
Retained Earnings (Accumulated Deficit)           71,827 $ 47,281                
Working capital           3,921                  
Stockholders' Equity Attributable to Parent           10,499 11,011 $ 8,999 $ 19,458 $ 8,367   $ 4,650 $ 6,263 $ 6,249  
Proceeds from issuance of financial instruments           16,438 10,685                
Recognized revenue           7,733 $ 5,031                
Third Party [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Fair value of convertible debt           $ 4,989                  
NIS [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Common Stock, Par or Stated Value Per Share | $ / shares           $ 0.01 $ 0.01                
Minimum [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Debt Instrument, Convertible, Conversion Price | $ / shares   $ 0.05                          
Todos Deposit Shares [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Common Stock, Par or Stated Value Per Share | $ / shares           $ 0.01                  
Fair value market deposit shares           $ 1,500                  
Number of shares issued as non-refundable | shares           25,862,069,000                  
Provista Diagnostics Inc [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Sale of stock, percentage       100.00%                      
Breakthrough Diagnostics Inc [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
[custom:PercentageOfIssuedAndOutstandingCommonStock-0]                             0.1999
[custom:RemainingPercentageOfIssuedAndOutstandingCommonStock-0]                     0.8001        
Share Purchase Agreement [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of shares issued as non-refundable | shares           29,296,875                  
Share Purchase Agreement [Member] | Provista Diagnostics Inc [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Sale of stock value of shares issued in transaction       $ 7,500                      
Share Purchase Agreement [Member] | Provista Diagnostics Inc [Member] | Preferred Stock [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Stock issued during period shares purchase | shares       3,599                      
Share Purchase Agreement [Member] | Provista Diagnostics Inc [Member] | Ordinary Stock [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Stock issued during period shares purchase | shares       1,581